RS52375B - Stable crystal of 4-oxoquinoline compund - Google Patents
Stable crystal of 4-oxoquinoline compundInfo
- Publication number
- RS52375B RS52375B RS20120306A RSP20120306A RS52375B RS 52375 B RS52375 B RS 52375B RS 20120306 A RS20120306 A RS 20120306A RS P20120306 A RSP20120306 A RS P20120306A RS 52375 B RS52375 B RS 52375B
- Authority
- RS
- Serbia
- Prior art keywords
- oxochinoline
- compound
- stable crystals
- ray powder
- dihydroquinoline
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 2
- -1 4-OXOCHINOLINE COMPOUND Chemical class 0.000 title 1
- 239000000843 powder Substances 0.000 abstract 2
- 238000010586 diagram Methods 0.000 abstract 1
- 238000002050 diffraction method Methods 0.000 abstract 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004150979 | 2004-05-20 | ||
| PCT/JP2005/009604 WO2005113508A1 (en) | 2004-05-20 | 2005-05-19 | Stable crystal of 4-oxoquinoline compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS52375B true RS52375B (en) | 2012-12-31 |
Family
ID=35079161
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20231092A RS64845B1 (sr) | 2004-05-20 | 2005-05-19 | Kombinacija koja se sastoji od stabilnog kristala 4-oksohinolinskog jedinjenja |
| RS20120306A RS52375B (en) | 2004-05-20 | 2005-05-19 | Stable crystal of 4-oxoquinoline compund |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20231092A RS64845B1 (sr) | 2004-05-20 | 2005-05-19 | Kombinacija koja se sastoji od stabilnog kristala 4-oksohinolinskog jedinjenja |
Country Status (33)
| Country | Link |
|---|---|
| US (7) | US7635704B2 (h) |
| EP (4) | EP4299563A3 (h) |
| JP (1) | JP3754064B2 (h) |
| KR (1) | KR20080064909A (h) |
| CN (1) | CN1956961B (h) |
| AR (2) | AR049280A1 (h) |
| AU (1) | AU2005245296B2 (h) |
| BE (1) | BE2024C511I2 (h) |
| BR (1) | BRPI0510114B8 (h) |
| CA (1) | CA2566922C (h) |
| CY (4) | CY1113010T1 (h) |
| DK (2) | DK1636190T3 (h) |
| ES (2) | ES2960824T3 (h) |
| FI (2) | FI3281939T3 (h) |
| FR (1) | FR23C1040I1 (h) |
| HR (2) | HRP20120681T1 (h) |
| HU (2) | HUE064615T2 (h) |
| IL (1) | IL179250A0 (h) |
| LT (1) | LT3281939T (h) |
| LU (1) | LUC00334I2 (h) |
| MX (1) | MXPA06013405A (h) |
| MY (1) | MY134672A (h) |
| NO (8) | NO339223B1 (h) |
| NZ (1) | NZ551839A (h) |
| PE (2) | PE20120361A1 (h) |
| PL (2) | PL3281939T3 (h) |
| PT (2) | PT1636190E (h) |
| RS (2) | RS64845B1 (h) |
| RU (1) | RU2330845C1 (h) |
| SI (2) | SI1636190T1 (h) |
| TW (1) | TWI329015B (h) |
| WO (1) | WO2005113508A1 (h) |
| ZA (1) | ZA200610647B (h) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6891227B2 (en) | 2002-03-20 | 2005-05-10 | International Business Machines Corporation | Self-aligned nanotube field effect transistor and method of fabricating same |
| EP2272516A3 (en) * | 2002-11-20 | 2011-03-16 | Japan Tobacco, Inc. | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| WO2007063869A1 (ja) * | 2005-11-30 | 2007-06-07 | Japan Tobacco Inc. | 高純度キノロン化合物の製造方法 |
| US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| AU2013203476C1 (en) * | 2005-12-30 | 2016-11-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| KR20140082858A (ko) | 2005-12-30 | 2014-07-02 | 길리애드 사이언시즈, 인코포레이티드 | Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법 |
| EP2452682A1 (en) | 2006-02-01 | 2012-05-16 | Japan Tobacco, Inc. | Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection |
| WO2007092802A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and gs 9137 |
| IN2014CN00613A (h) | 2006-03-06 | 2015-08-21 | Japan Tobacco Inc | |
| US8420821B2 (en) | 2006-03-06 | 2013-04-16 | Japan Tobacco Inc. | Process for production of 4-oxoquinoline compound |
| US7939553B2 (en) | 2006-07-07 | 2011-05-10 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| WO2008033836A2 (en) | 2006-09-12 | 2008-03-20 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| PT2118082E (pt) * | 2007-02-23 | 2014-12-12 | Gilead Sciences Inc | Moduladores de propriedades farmacocinéticas de terapêuticas |
| KR20100040892A (ko) * | 2007-06-29 | 2010-04-21 | 길리애드 사이언시즈, 인코포레이티드 | 치료 조성물 및 그의 용도 |
| EP2167089A1 (en) * | 2007-06-29 | 2010-03-31 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| CA2720856C (en) | 2008-05-02 | 2016-02-02 | Gilead Sciences, Inc. | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| MX2011008289A (es) | 2009-02-06 | 2011-09-15 | Gilead Sciences Inc | Tabletas para terapia combinada. |
| WO2010137032A2 (en) * | 2009-05-14 | 2010-12-02 | Matrix Laboratories Ltd. | Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts |
| WO2011004389A2 (en) * | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | An improved process for the preparation of elvitegravir |
| CN102212032B (zh) * | 2011-04-20 | 2013-07-31 | 复旦大学 | 一种5-羟基喹诺酮类衍生物及其制备方法和用途 |
| RU2015103913A (ru) | 2012-07-06 | 2016-08-27 | Дженентек, Инк. | N-замещенные бензамиды и способы их применение |
| EA026089B1 (ru) | 2012-08-03 | 2017-02-28 | Джилид Сайэнс, Инк. | Способ и промежуточные соединения для получения ингибиторов интегразы |
| CN103819402B (zh) * | 2012-11-17 | 2016-03-30 | 上海迪赛诺化学制药有限公司 | 埃替拉韦中间体及其制备方法和应用 |
| CN103864682B (zh) * | 2012-12-18 | 2016-12-28 | 上海迪赛诺化学制药有限公司 | 一种制备iii型埃替拉韦晶体的方法 |
| CN111303152B (zh) | 2012-12-21 | 2023-04-11 | 吉利德科学公司 | 多环-氨基甲酰基吡啶酮化合物及其药物用途 |
| NO2865735T3 (h) | 2013-07-12 | 2018-07-21 | ||
| ES2645192T3 (es) | 2013-07-12 | 2017-12-04 | Gilead Sciences, Inc. | Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH |
| CN105315203A (zh) * | 2014-06-06 | 2016-02-10 | 上海迪赛诺化学制药有限公司 | 一种v型埃替拉韦晶体及其制备方法 |
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| NO2717902T3 (h) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| HK1249103B (en) | 2015-04-02 | 2020-02-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| CN106008195B (zh) * | 2016-05-19 | 2018-08-03 | 绍兴文理学院 | 一种2，4-二氟-5-碘苯甲酸的制备方法 |
| EP3984536B1 (en) * | 2020-10-19 | 2025-06-25 | Centre national de la recherche scientifique | Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3472859A (en) * | 1966-11-01 | 1969-10-14 | Sterling Drug Inc | 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters |
| JPS567162B1 (h) | 1970-09-14 | 1981-02-16 | ||
| JPS4826772A (h) | 1971-08-11 | 1973-04-09 | ||
| JPS6450979A (en) | 1987-08-21 | 1989-02-27 | Hitachi Shipbuilding Eng Co | Method for discriminating whistle sound |
| JPH0651229B2 (ja) | 1989-07-31 | 1994-07-06 | 新日本製鐵株式会社 | プラズマアーク溶接方法および装置 |
| IL100555A (en) | 1991-02-07 | 2000-08-31 | Hoechst Marion Roussel Inc | N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them |
| NO304832B1 (no) * | 1992-05-27 | 1999-02-22 | Ube Industries | Aminokinolonderivater samt middel mot HIV |
| JP2993316B2 (ja) | 1992-05-27 | 1999-12-20 | 宇部興産株式会社 | アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤 |
| JPH06199835A (ja) | 1993-01-08 | 1994-07-19 | Hokuriku Seiyaku Co Ltd | ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体 |
| JPH06271568A (ja) | 1993-03-22 | 1994-09-27 | Hokuriku Seiyaku Co Ltd | ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体 |
| HUT76643A (en) * | 1994-07-18 | 1997-10-28 | Sankyo Co | Trifluoromethylquinolinecarboxylic acid derivative, pharmaceutical compositions containing them and their use |
| JP2930539B2 (ja) | 1994-07-18 | 1999-08-03 | 三共株式会社 | トリフルオロメチルキノリンカルボン酸誘導体 |
| JPH0826772A (ja) | 1994-07-22 | 1996-01-30 | Sony Corp | 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法 |
| US6187775B1 (en) | 1996-04-12 | 2001-02-13 | The United States Of America As Represented By The Department Of Health And Human Services | Acridone-derived compounds useful as antineoplastic and antiretroviral agents |
| FR2761687B1 (fr) * | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
| JP3776203B2 (ja) | 1997-05-13 | 2006-05-17 | 第一製薬株式会社 | Ｉｃａｍ−１産生阻害剤 |
| GB9721964D0 (en) * | 1997-10-16 | 1997-12-17 | Pfizer Ltd | Isoquinolines |
| US6399629B1 (en) | 1998-06-01 | 2002-06-04 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
| SE9802549D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6248736B1 (en) * | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
| US6248739B1 (en) * | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
| PE20011349A1 (es) | 2000-06-16 | 2002-01-19 | Upjohn Co | 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales |
| US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| DE60124577T2 (de) | 2000-10-12 | 2007-09-27 | Merck & Co., Inc. | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
| CA2425067A1 (en) | 2000-10-12 | 2002-05-10 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors |
| ATE411292T1 (de) | 2001-03-01 | 2008-10-15 | Shionogi & Co | Stickstoffhaltige heteroarylverbindungen mit hiv- integrase inhibierender wirkung |
| JP2002293745A (ja) | 2001-03-29 | 2002-10-09 | St Marianna Univ School Of Medicine | 慢性関節リウマチ治療剤 |
| US20030138483A1 (en) * | 2001-05-25 | 2003-07-24 | Sergio Petriconi | Soft elastic capsules and compositions thereof |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| FR2827600A1 (fr) | 2001-07-20 | 2003-01-24 | Lipha | Derives acides de quinolone et leurs applications en therapeutique |
| RU2206564C1 (ru) * | 2002-03-07 | 2003-06-20 | Общество с ограниченной ответственностью "Поливит" | Способ получения этилового эфира 6-фтор-7-хлор-1,4-дигидро-4-оксо-3-хинолинкарбоновой кислоты |
| JP4035765B2 (ja) | 2002-10-31 | 2008-01-23 | 横河電機株式会社 | フーリエ変換型赤外線分光計 |
| JP3567162B1 (ja) | 2002-11-20 | 2004-09-22 | 日本たばこ産業株式会社 | ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用 |
| EP2272516A3 (en) * | 2002-11-20 | 2011-03-16 | Japan Tobacco, Inc. | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| WO2005113509A1 (en) * | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| US8633219B2 (en) * | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
-
2005
- 2005-05-18 MY MYPI20052258A patent/MY134672A/en unknown
- 2005-05-19 ZA ZA200610647A patent/ZA200610647B/en unknown
- 2005-05-19 CA CA2566922A patent/CA2566922C/en not_active Expired - Lifetime
- 2005-05-19 TW TW094116234A patent/TWI329015B/zh not_active IP Right Cessation
- 2005-05-19 PL PL17186674.2T patent/PL3281939T3/pl unknown
- 2005-05-19 RS RS20231092A patent/RS64845B1/sr unknown
- 2005-05-19 AR ARP050102058A patent/AR049280A1/es not_active Application Discontinuation
- 2005-05-19 JP JP2005147219A patent/JP3754064B2/ja not_active Expired - Lifetime
- 2005-05-19 ES ES17186674T patent/ES2960824T3/es not_active Expired - Lifetime
- 2005-05-19 AU AU2005245296A patent/AU2005245296B2/en active Active
- 2005-05-19 EP EP23203885.1A patent/EP4299563A3/en active Pending
- 2005-05-19 LT LTEP17186674.2T patent/LT3281939T/lt unknown
- 2005-05-19 MX MXPA06013405A patent/MXPA06013405A/es active IP Right Grant
- 2005-05-19 RU RU2006145302/04A patent/RU2330845C1/ru active
- 2005-05-19 FI FIEP17186674.2T patent/FI3281939T3/fi active
- 2005-05-19 EP EP12173572A patent/EP2514746A1/en not_active Withdrawn
- 2005-05-19 WO PCT/JP2005/009604 patent/WO2005113508A1/en active Application Filing
- 2005-05-19 HR HRP20120681TT patent/HRP20120681T1/hr unknown
- 2005-05-19 KR KR1020087014768A patent/KR20080064909A/ko not_active Withdrawn
- 2005-05-19 SI SI200531572T patent/SI1636190T1/sl unknown
- 2005-05-19 ES ES05726243T patent/ES2388441T3/es not_active Expired - Lifetime
- 2005-05-19 EP EP17186674.2A patent/EP3281939B1/en not_active Expired - Lifetime
- 2005-05-19 NZ NZ551839A patent/NZ551839A/en not_active IP Right Cessation
- 2005-05-19 PT PT05726243T patent/PT1636190E/pt unknown
- 2005-05-19 RS RS20120306A patent/RS52375B/en unknown
- 2005-05-19 DK DK05726243.8T patent/DK1636190T3/da active
- 2005-05-19 SI SI200532315T patent/SI3281939T1/sl unknown
- 2005-05-19 DK DK17186674.2T patent/DK3281939T3/da active
- 2005-05-19 EP EP05726243A patent/EP1636190B1/en not_active Expired - Lifetime
- 2005-05-19 PT PT171866742T patent/PT3281939T/pt unknown
- 2005-05-19 CN CN2005800161426A patent/CN1956961B/zh not_active Expired - Lifetime
- 2005-05-19 BR BRPI0510114A patent/BRPI0510114B8/pt active IP Right Grant
- 2005-05-19 HR HRP20231588TT patent/HRP20231588T3/hr unknown
- 2005-05-19 PL PL05726243T patent/PL1636190T3/pl unknown
- 2005-05-19 HU HUE17186674A patent/HUE064615T2/hu unknown
- 2005-05-20 PE PE2011002129A patent/PE20120361A1/es active IP Right Grant
- 2005-05-20 US US11/133,471 patent/US7635704B2/en active Active
- 2005-05-20 PE PE2005000561A patent/PE20060358A1/es active IP Right Grant
-
2006
- 2006-11-14 IL IL179250A patent/IL179250A0/en active IP Right Grant
- 2006-12-14 NO NO20065790A patent/NO339223B1/no unknown
-
2009
- 2009-08-10 US US12/538,694 patent/US8981103B2/en active Active
-
2012
- 2012-07-11 CY CY20121100621T patent/CY1113010T1/el unknown
-
2014
- 2014-04-25 AR ARP140101722A patent/AR096100A2/es active IP Right Grant
-
2015
- 2015-01-09 US US14/593,946 patent/US20150361044A1/en not_active Abandoned
-
2016
- 2016-08-12 NO NO20161297A patent/NO20161297A1/no not_active Application Discontinuation
-
2017
- 2017-03-01 US US15/447,007 patent/US20180029989A1/en not_active Abandoned
-
2018
- 2018-07-20 US US16/041,458 patent/US20190185433A1/en not_active Abandoned
-
2019
- 2019-01-15 NO NO20190051A patent/NO20190051A1/no not_active Application Discontinuation
-
2020
- 2020-08-04 NO NO20200873A patent/NO20200873A1/no not_active Application Discontinuation
-
2021
- 2021-08-24 US US17/445,817 patent/US20220235009A1/en not_active Abandoned
-
2022
- 2022-06-17 NO NO20220690A patent/NO20220690A1/no not_active Application Discontinuation
-
2023
- 2023-08-25 NO NO20230913A patent/NO347902B1/no unknown
- 2023-09-28 CY CY2015009C patent/CY2015009I1/el unknown
- 2023-11-02 FR FR23C1040C patent/FR23C1040I1/fr active Active
- 2023-12-05 CY CY20231100714T patent/CY1126560T1/el unknown
-
2024
- 2024-03-14 LU LU00334C patent/LUC00334I2/fr unknown
- 2024-03-15 BE BE2024C511C patent/BE2024C511I2/nl unknown
- 2024-03-19 CY CY2024008C patent/CY2024008I2/el unknown
- 2024-03-20 FI FIC20240008C patent/FIC20240008I1/fi unknown
- 2024-03-20 HU HUS2400006C patent/HUS2400006I1/hu unknown
- 2024-04-12 US US18/634,451 patent/US20250091995A1/en active Pending
- 2024-04-22 NO NO20240384A patent/NO20240384A1/no unknown
- 2024-07-15 NO NO2024034C patent/NO2024034I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS52375B (en) | Stable crystal of 4-oxoquinoline compund | |
| HRP20210748T1 (hr) | Postupak priprave spojeva s aktivnošću inhibitora hiv integraze | |
| EA200802119A1 (ru) | Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат | |
| EA200601273A1 (ru) | Новая кристаллическая форма v агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
| EA200601274A1 (ru) | Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
| EA200601271A1 (ru) | Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
| MY186531A (en) | Crystals | |
| EA200300107A1 (ru) | Кристаллические формы трет-бутиламиновой соли периндоприла | |
| CY1124868T1 (el) | Σταθερη κρυσταλλικη μορφη υδροχλωρικης τιπιρακιλης και μεθοδος κρυσταλλωσης για αυτην | |
| DK2170769T3 (da) | Krystalliseret faststof IZM-2 og fremgangsmåde til fremstilling deraf | |
| EA200901609A1 (ru) | Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов | |
| MX2010002902A (es) | Pirimidinas anti-infecciosas y usos de las mismas. | |
| RS53415B (en) | NALMEFEN HYDROCHLORIDE DIHYDRATE | |
| MX2008008298A (es) | Sal de sulfato de hidrogeno novedosa. | |
| EA201101304A1 (ru) | Новая кристаллическая форма vi агомелатина, ее получение и применение | |
| WO2007016539A3 (en) | Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase | |
| WO2014136282A8 (en) | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient | |
| UA89905C2 (ru) | α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕЕ СОДЕРЖИТ | |
| EA200901375A1 (ru) | Производные пиридазина, пиридина и пирана в качестве агонистов рецептора gpbar1 | |
| ES2650604T3 (es) | Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene | |
| MX2023004668A (es) | Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico. | |
| EA200900936A1 (ru) | Аморфные и кристаллические формы ривастигмина гидротартрата | |
| SG178880A1 (en) | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use | |
| AR063006A1 (es) | Modificacion cristalina de 4-{[(6-cloropiridin-3-il)metil](metil)amino}furan-2(5h)-ona | |
| WO2006053625A8 (en) | Crystalline form of cefdinir ammonium salt as an intermediate for the preparation of pure cefdinir |